Iktos acquires Synsight, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery.
The merger further complements Iktos' AI-based drug discovery platform, that currently includes generative AI design, Retrosynthesis, and AI-driven automated synthesis capabilities by adding the key step of automated biological testing thanks to MT Bench technology originally developed at INSERM.
To learn more about this acquisition follow this link.
